Technology Guidance

Dolutegravir with lamivudine

for treating Human Immunodeficiency Virus type 1 (HIV-1) infection

Technology Guidance from the MOH Drug Advisory Committee

Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has recommended:

- ✓ Dolutegravir 50 mg/lamivudine 300 mg tablet for treating Human Immunodeficiency Virus type 1 (HIV-1) infection

in view of acceptable proposal from the company.

Funding status

Dolutegravir 50 mg/lamivudine 300 mg tablet is recommended for inclusion on the MOH Standard Drug List (SDL) from 1 February 2023.

Information on antiretroviral therapies previously recommended by the Drug Advisory Committee can be found in the Technology Guidance published on 1 September 2020 (Antiretroviral therapies for treating Human Immunodeficiency Virus type 1 (HIV-1) infection)

Published: 19 December 2022

Agency for Care Effectiveness - ACE Agency for Care Effectiveness (ACE)

About the Agency

The Agency for Care Effectiveness (ACE) was established by the Ministry of Health (Singapore) to drive better decision-making in healthcare through health technology assessment (HTA), clinical guidance, and education.

As the national HTA agency, ACE conducts evaluations to inform government subsidy decisions for treatments, diagnostic tests and vaccines, and produces guidance for public hospitals and institutions in Singapore.

This guidance is based on the evidence available to the MOH Drug Advisory Committee as at 12 October 2022. It is not, and should not be regarded as, a substitute for professional or medical advice. Please seek the advice of a qualified healthcare professional about any medical condition. The responsibility for making decisions appropriate to the circumstances of the individual patient remains with the healthcare professional.

Find out more about ACE at www.ace-hta.gov.sg/about

Chief HTA Officer
Agency for Care Effectiveness
Email: ACE_HTA@moh.gov.sg